Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fractional intradermal versus full-dose intramuscular recombinant shingles vaccination
NL-OMON61654Phase 3Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Oct 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of Zoster vaccine recombinant in herpes zoster (HZ) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Primary immunogenicity endpoint. Started Oct 2026; status: recruiting.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NL-OMON61654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61654.